Is Zepbound available in Australia?
No. Zepbound is Eli Lilly's US brand of tirzepatide for weight, and it isn't on Australia's register of medicines. In Australia, tirzepatide is sold as Mounjaro, registered for type 2 diabetes, chronic weight management since September 2024, and sleep apnoea with obesity. It's the same medicine under a different brand.
What does the Australian register show?
A search of the register for tirzepatide on 12 October 2026 returned 18 products, all of them Mounjaro.1
They are single-dose pens, vials and multi-dose KwikPens.1 The TGA decided on Mounjaro's weight-management use on 9 September 2024.2 The sleep apnoea use was reported in June 2025.3 The label's weight criteria are a BMI of 30 or more, or 27 or more with a weight-related condition. In October 2026 the label also added type 2 diabetes in children aged 10 and over who weigh at least 50 kg.4
What is Zepbound?
Zepbound is tirzepatide from Eli Lilly, approved by the US Food and Drug Administration on 8 November 2023.5
The US has separate brands for diabetes (Mounjaro) and weight (Zepbound). Australia uses the one name, Mounjaro, for both, and both brands come from the same company.1,4,5 So if you've read about Zepbound in US news, the Australian equivalent is Mounjaro, with the Australian label's own rules on who it's for.4
Why does the name matter?
A product sold online as “Zepbound” in Australia isn't a registered medicine here, and the TGA warns that imported GLP‑1 products may be fake.1,6
Compounded tirzepatide isn't a lawful alternative: pharmacists have been barred from compounding any GLP‑1 medicine since 1 October 2024.7 The TGA advises buying prescription medicines only from a local registered pharmacy.6 Mounjaro is not on the PBS; see Is Mounjaro on the PBS? Because it isn't PBS-listed, a Mounjaro script is paid in full, and a pharmacist can tell you the price.8,9 Who can prescribe it is in Can my GP prescribe Mounjaro? The medicines are compared in Guide 2.
Read the full picture
Related questions
Sources
- TGA. ARTG search for 'tirzepatide': 18 results, all Mounjaro, checked 12 Oct 2026. tga.gov.au
- TGA. AusPAR: Mounjaro (tirzepatide), chronic weight management. Decision 9 Sep 2024, ARTG entry 10 Sep 2024. tga.gov.au
- newsGP (RACGP). Mounjaro approved to treat sleep apnoea, 4 Jun 2025. racgp.org.au
- Eli Lilly. Mounjaro and Mounjaro KwikPen (tirzepatide) Australian Product Information, vA14.0, date of revision 2 Oct 2026, sections 2, 4.1, 4.2, 4.5, 4.8, 6.4 to 6.6. Australian label. medsinfo.com.au (PDF)
- US FDA. Drugs@FDA: NDA 217806, Zepbound (tirzepatide), Eli Lilly. Original approval 8 Nov 2023. accessdata.fda.gov
- TGA. Counterfeit weight loss products claiming to contain GLP-1. Safety advisory, 2 Mar 2026. tga.gov.au
- TGA. Update on the GLP-1 RA pharmacy compounding changes. Media release, 18 Jun 2024. tga.gov.au
- PBS. Medicine status: tirzepatide (Mounjaro), type 2 diabetes, document 1609. Page last updated 30 Sep 2026. pbs.gov.au
- TGA. Applying the Advertising Code rules: price information. Updated 21 Jul 2026. tga.gov.au
Last checked 12 Oct 2026 · Next review due 12 Oct 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on 12 Oct 2026. We don't publish medicine prices, and we don't name, rank or link to sellers or telehealth services. It's general information, not medical advice, and nothing here is an offer to supply any medicine. Talk to a GP, pharmacist or other qualified prescriber before starting, stopping or changing any medicine. How we write